Safety and Pharmacology Study of SNX-5422 in Subjects With Refractory Hematological Malignancies

Inclusion Criteria: * Males or non-pregnant, non-breastfeeding females 18 years-of-age or older with histologically confirmed non-Hodgkins lymphoma, without known or clinically suspected CNS involvement, that is refractory to available therapy or for which there is no available therapy. * No more than 4 prior lines of systemic anti-cancer therapy and no prior bone marrow transplant or stem cell transplant within 12 months of dosing, and no prior allogeneic transplant. * Karnofsky performance score ≥60 * Life expectancy of at least 3 months. * Adequate baseline laboratory assessments Exclusion Criteria: * Currently receiving anticancer therapy or have received anticancer therapy within the past 28 days or 5 half-lives of the anticancer therapy * The need for treatment with medications with clinically-relevant metabolism by the cytochrome P450 (CYP) 3A4 isoenzyme within 3 hours before or after administration of SNX-5422 * At increased risk for developing prolonged QT interval, including hypokalemia or hypomagnesemia, unless corrected to within normal limits prior to first dose of SNX-• Chronic diarrhea. * Gastrointestinal diseases or conditions that could affect drug absorption, including gastric bypass. * Gastrointestinal diseases that could alter the assessment of safety, including irritable bowel syndrome, ulcerative colitis, Crohn's disease, or hemorrhagic coloproctitis. * History of documented adrenal dysfunction not due to malignancy. * Seropositive for human immunodeficiency virus (HIV) or hepatitis C virus (HCV). * History of chronic liver disease